Fidaxomicin reduces C. difficile environmental contamination

It is well-established that fidaxomicin reduces the recurrence rate of C. difficile infection (CDI), but this study from my old research group at GSTT / KCL is the first to evaluate the impact of treatment with fidaxomicin on environmental contamination. The bottom line is that patients treated with fidaxomicin had less C. difficile contamination than patients treated with vancomycin / metronidazole.

In total, the rooms of 38 / 66 (57.6%) patients treated with metronidazole / vancomycin had one or more positive environmental cultures compared with 25 / 68 (36.8%) patients treated with fidaxomicin (P = 0.02). Similarly, when considering all of the sampled environmental sites (four per room), 68 / 264 (25.8%) were positive in patients treated with metronidazole / vancomycin compared with 47 / 272 (17.3%) in patients treated with fidaxomicin (P = 0.02) (see Figure below).

Fidax CDI

Figure: Environmental contamination with C. difficile in the rooms of patients treated with fidaxomicin vs. vancomycin / metronidazole.

Continue reading

What’s lurking in the hospital environment? The importance of cleaning and disinfection in infection prevention and control

image

I was asked to speak to a group of link nurses at Southampton Hospital earlier in the week, and thought I’d share my slides, here.

I am passionate about the importance of surface contamination in transmission: I still think it’s really under-rated. I am pretty sure that most healthcare workers would have no idea that your chances of acquiring C. difficile infection (and others) is influenced by who used the room or bed space before you. And who would believe that VRE could survive on a dry surface for 4 years? Or that touching a surface is as important as touching the patient in terms of acquiring contamination on your hands?

Continue reading

What drives carbapenem resistance? Carbapenem use, stupid!

An outstanding study from colleagues at Imperial shows that if you use a bucket-load of meropenem (a carbapenem antibiotic) one year, you see an uptick in carbapenem-resistant Enterobacteriaceae (CRE) the next. The figure below plots meropenem use in the previous year with the incidence rate of OXA-48 producing K. pneumoniae CRE.

mero usage correlation

Figure: The use of meropenem in the previous year plotted against the incidence rate of OXA-48 producing K. pneumoniae

Continue reading

European approaches to MDR-GNR prevention and control

HISME

I was privileged to be asked to speak at the inaugural Healthcare Infection Society Middle East Summit in Dubai this week on ‘European approaches to MDR-GNR prevention and control’. You can download my slides here.

I began with a (probably too lengthy) preamble outlining some overall points:

  • CRE is a big deal in Europe, especially in the UK, and has prompted unprecedented action on a national level in the form of a Toolkit, a Patient Safety Alert and a letter to all CEOs requesting (demanding?) an action plan. The political picture is similar elsewhere in Europe and in the USA. Although this level of government scrutiny can be challenging, on the whole I think it’s beneficial, and is probably a sizeable factor in the successes achieved with MRSA and CDI.
  • Do we go universal or targeted? There’s been much discussion recently about abandoning traditional targeted (aka vertical) approaches in favour of universal (aka horizontal). Interesting, all guidelines that I could lay my hands on favoured a targeted approach for MDR-GNR, centred around screening and isolation of carriers.
  • Where is the evidence? We are hamstrung by the lack of high quality studies telling us with any certainty what works to control MDR-GNR. Pretty much all studies to date are either performed in an outbreak setting (regression to the mean…) or include multiple interventions (which worked?), or both. The few studies that evaluated a single intervention in an endemic setting are underpowered to deliver a meaningful conclusion. So, we need bigger and better studies!
  • How do you produce good guidelines – who is on the guideline writing dream team, and what are the key pitfalls to avoid. Plus, importantly, how to good guidelines translate through a good policy into good practice?

Continue reading

‘Crapsules’: the cure for Cdiff and more

crapsules brown pills

I gave a talk today at a Pint of Science event entitled “Crapsules: the cure for Cdiff and more”. You can download my slides here. Cdiff infection (CDI) is a nasty disease, usually occurring in those who have taken antibiotics in hospital. It’s characterised by frequent loose stools (often 5 or more movements per day) and frequent recurrence. Around 15-35% of patients with CDI will have a repeat episode. The mainstay treatment for recurrent CDI is antibiotics but the cure rate is poor at around 30%. Remarkably a ‘faecal microbiota transplantation’ (FMT) is way more effective, with a cure rate in excess of 90%.

Continue reading

CRE: coming to a hospital near you

carbapenemase

I thought for quite some time about whether the title to this post ought to be a statement or a question. I decided on a statement: pretty much wherever you are in the world, I am certain that CRE is now one (hospital) degree of separation from you.

I gave this talk yesterday at the imaginatively named “Darling Bugs of May” IPS conference, and you can download my slides here. I’ve given similar talks before, but the whole thing took on greater significance now I have had some first hand experience of making decisions around the management of CRE patients.

Continue reading

Are beards bug traps? Au contraire!

As the owner of a relatively new beard (see picture below), I was alarmed to hear that my beard is probably as contaminated with faeces as a toilet brush. Fortunately, a Journal of Hospital Infection study from 2014 turns this on its head, showing that those wearing beards are actually less likely to be colonised with staphylococci!

Me and my beard

Twitter01f6551v2

Continue reading

Voss + Kiernan + Otter = Reflections on Infection Prevention and Control!

ReflectionsIPC

Not so long ago, we (that is Andreas Voss, Martin Kiernan and Jon Otter) put our heads together and started talking along the lines of “a team is greater than the sum of its parts”…and the “Reflections” blog was conceived.

We are all keen bloggers with hopefully complimentary interests and expertise so we hope that you will enjoy our new blog.

Do please sign up for email notifications and look out for tweets hashtagged #ReflectionsIPC.

Also, please submit lots of comments – we love the discussion.

Finally, if you have something that you want to get off your chest, we’d love to host some Guest Blogs from time to time, so do get in touch.

The cat and mouse of antibiotic resistance (Tom never does catch Jerry…)

tom and jerryProf Laura Piddock’s team from Birmingham recently published a Nature review on molecular mechanisms of antibiotic resistance. If you’re struggling to tell your KPC from your NDM, this review is for you. Continue reading

What does it take to get an infection prevention and control service into shape?

mrsaWhilst the organisation of an infection control service isn’t everybody’s cup of tea, it is mine now. So, what are the key elements of a successful programme? A thoughtful review in Lancet ID penned by an all-star cast (including Zingg, Holmes & Pittet to name but a few) provides a framework for answering this question. Their systematic review yielded 10 key components:

  1. Organisation of infection control at the hospital level;
  2. Bed occupancy, staffing, workload, and employment of pool or agency nurses;
  3. Availability of and ease of access to materials and equipment and optimum ergonomics;
  4. Appropriate use of guidelines;
  5. Education and training;
  6. Auditing;
  7. Surveillance and feedback;
  8. Multimodal and multidisciplinary prevention programmes that include behavioural change;
  9. Engagement of champions;
  10. Positive organisational culture.

None of these are especially surprising, or that difficult to implement. It’s strange in a way that we know from multiple studies that high bed occupancy results in more transmission (specifically of MRSA). So why don’t we just reduce the rate of bed occupancy? If you account for the extended length of stay for patients who become infected, it would probably result in a net increase in patient throughput. Similarly, understaffing results in more transmission (again, specifically of MRSA). So why don’t we just make sure we hit adequate levels of staffing? I suspect the answer here is short-sighted accountancy combined with a genuine lack of the right staff to fill the necessary vacancies.

I’ve always found it a bit odd that the mere act of performing surveillance and reporting the results back to wards reduces HCAI – but there’s a fair amount of data behind this. I suspect it has to do with the type of people we are dealing with: busy healthcare professionals. If their unit’s rate of MRSA (or whatever) is, in the politest possible sense, in their face, they’re more likely to do something about it.

Finally, nurturing a positive organisational culture is crucial but somewhat philosophical. How do you measure whether your organisation has a positive culture? Perhaps perception is reality here, so the best approach is probably to consider organisational positivity as a highly transmissible infectious agent!